Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

This study has been completed.

Sponsor:

Information provided by:

National Institute on Drug Abuse (NIDA)

ClinicalTrials.gov Identifier:

NCT00292123

First received: February 14, 2006

Last updated: April 30, 2013

Last verified: December 2007

History of Changes

Purpose

The primary goal of this study is to determine how contingency management can best be combined with standard or high doses of methadone to increase simultaneous abstinence from heroin and cocaine.

Condition	Intervention	Phase
Opioid Dependence Cocaine Abuse	Drug: Methadone Behavioral: Contingency Management	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment

Resource links provided by NLM:

Drug Information available for: Methadone Methadone hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Enrollment:	200
Study Start Date:	June 1999
Study Completion Date:	August 2006
Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Detailed Description:

A study of people pmaintained on Methadone using contingency management

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Opioid dependence; cocaine use

Exclusion Criteria:

Medical or psychiatric conditions that would contraindicate participation in a methadone maintenance study; inability to give informed consent; inability to attend clinic seven days a week

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00292123

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator:

Kenzie Preston, PhD

NIFA Intramural Research Program

More Information

Publications:

Ghitza UE, Epstein DH, Preston KL. Contingency management reduces injection-related HIV risk behaviors in heroin and cocaine using outpatients. Addict Behav. 2007 Nov 17; [Epub ahead of print]

Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL. Hepatitis C and HIV risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat. 2007 Oct 9; [Epub ahead of print]

Ghitza UE, Epstein DH, Schmittner J, Vahabzadeh M, Lin JL, Preston KL. Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin. J Consult Clin Psychol. 2007 Oct;75(5):765-74.

Ghitza UE, Epstein DH, Preston KL. Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend. 2007 Dec 1;91(2-3):169-77. Epub 2007 Jul 10.

Heinz A, Epstein DH, Preston KL. Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs. 2007 Mar;39(1):41-9.

Heinz AJ, Epstein DH, Schroeder JR, Singleton EG, Heishman SJ, Preston KL. Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat. 2006 Dec;31(4):355-64. Epub 2006 Aug 1.

Ghitza UE, Epstein DH, Preston KL. Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav. 2007 May;32(5):938-49. Epub 2006 Aug 1.

Responsible Party:	Kenzie L. Preston, Ph.D., Principal Investigator, National Institute on Drug Abuse
ClinicalTrials.gov Identifier:	NCT00292123 History of Changes
Other Study ID Numbers:	NIDAIRP 326
Study First Received:	February 14, 2006
Last Updated:	April 30, 2013
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Methadone
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents
Narcotics

ClinicalTrials.gov processed this record on May 19, 2013

To Top